Smith & Nephew launches CARTIHEAL before Smith & Nephew stock results
Published on 10/18/2026 at 13:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEurope launch and earnings calendar
- CARTIHEAL became commercially available in Europe on October 6, 2026.
- Q3 2026 revenue consensus is USD 1,552 million with 3.3 percent underlying growth.
- Smith+Nephew plans to release its Q3 trading report on November 4, 2026.
Smith & Nephew (ISIN GB0009223206) said CARTIHEAL is commercially available in Europe across 12 countries from October 6, 2026, according to Smith+Nephew. The cartilage repair implant adds a concrete product milestone ahead of the company's next trading update.
Europe launch adds a product milestone
CARTIHEAL AGILI-C is designed for chondral and osteochondral knee repair, placing the launch inside Smith & Nephew's Orthopaedics business. The company operates across Advanced Wound Management, Sports Medicine and ENT, and Orthopaedics, according to its investor information.
The launch follows a first-half 2026 revenue figure of USD 3.10 billion, up 4.60 percent from the first half of 2025. Markets Insider reported quarterly revenue of USD 3.10 billion and net profit of USD 303.00 million for the quarter ended June 27, 2026.
What does the launch mean?
The immediate investor test is execution against the Q3 consensus. Smith & Nephew lists average Q3 2026 revenue of USD 1,552 million and underlying growth of 3.3 percent among 14 analysts as of October 2, 2026, according to Smith+Nephew.
Three dated company developments
In December 2025, Smith & Nephew set out its RISE strategy with four priorities: reach, innovate, scale and execute. On June 27, 2026, first-half revenue reached USD 3.10 billion, up 4.60 percent year over year. On October 6, 2026, the company announced commercial availability of CARTIHEAL AGILI-C in Europe, according to Smith+Nephew.
Next reporting date
Smith & Nephew plans to release its third-quarter 2026 trading report on November 4, 2026, at 7:00 a.m. GMT, according to Smith+Nephew. The company also expects average full-year 2026 revenue of USD 6,453 million and a trading margin of 19.8 percent in the published consensus.
Stock context before results
The CARTIHEAL launch gives the November report a product and execution angle. The figures investors will compare are the USD 1,552 million Q3 revenue consensus and the 3.3 percent underlying-growth estimate, while the full-year consensus points to USD 6,453 million of revenue.
Upcoming trading update
The next quantified test is the Q3 revenue forecast and its underlying-growth assumption. Smith & Nephew plans to publish the report on November 4, 2026, with the presentation scheduled for the same day.
The further course of trading is shown by the continuously updated real-time quote of Smith & Nephew stock.
Smith & Nephew stock facts
- Company: Smith & Nephew plc
- ISIN: GB0009223206
- WKN: 502816
- Ticker: SN
- Primary exchange: London Stock Exchange
- Sector / Industry: Health care / Medical technology
- Index membership: FTSE 100
Market context: Market report FTSE 100.
